Paraoxonase (PON)-1: a brief overview on genetics, structure, polymorphisms and clinical relevance

被引:100
作者
Shunmoogam, Nelusha [1 ]
Naidoo, Poobalan [1 ]
Chilton, Robert [2 ]
机构
[1] Sanofi, Sanofi House,2 Bond St, ZA-1685 Midrand, South Africa
[2] Univ Texas Hlth Sci Ctr San Antonio, Div Cardiol & Intervent Cardiol, Dept Med, San Antonio, TX 78229 USA
关键词
antioxidant; inflammation; atherosclerosis; cardiovascular disease;
D O I
10.2147/VHRM.S165173
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Paraoxonase-1 (PON1) is a high-density lipoprotein-associated esterase and is speculated to play a role in several human diseases including diabetes mellitus and atherosclerosis. Low PON1 activity has been associated with increased risk of major cardiovascular events, therefore a variety of studies have been conducted to establish the cardioprotective properties and clinical relevance of PON1. The major aim of this review was to highlight the important studies and to subsequently assess if PON1 has clinical relevance. A review of the literature showed that there is currently insufficient data to suggest that PON1 has clinical relevance. It is our opinion that robust studies are required to clarify the clinical relevance of PON1.
引用
收藏
页码:137 / 143
页数:7
相关论文
共 51 条
[2]   Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development [J].
Aviram, M ;
Rosenblat, M .
FREE RADICAL BIOLOGY AND MEDICINE, 2004, 37 (09) :1304-1316
[3]   PON1 activities and oxidative markers of LDL in patients with angiographic ally proven coronary artery disease [J].
Azarsiz, E ;
Kayikcioglu, M ;
Payzin, S ;
Sözmen, EY .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2003, 91 (01) :43-51
[4]   ROLE OF OXIDATIVE STRESS IN DEVELOPMENT OF COMPLICATIONS IN DIABETES [J].
BAYNES, JW .
DIABETES, 1991, 40 (04) :405-412
[5]   Active Site Hydrophobicity and the Convergent Evolution of Paraoxonase Activity in Structurally Divergent Enzymes: The Case of Serum Paraoxonase 1 [J].
Blaha-Nelson, David ;
Kruger, Dennis M. ;
Szeler, Klaudia ;
Ben-David, Moshe ;
Kamerlin, Shina Caroline Lynn .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2017, 139 (03) :1155-1167
[6]   Paraoxonase-1 is a major determinant of clopidogrel efficacy [J].
Bouman, Heleen J. ;
Schoemig, Edgar ;
van Werkum, Jochem W. ;
Velder, Janna ;
Hackeng, Christian M. ;
Hirschhaeuser, Christoph ;
Waldmann, Christopher ;
Schmalz, Hans-Guenther ;
ten Berg, Jurrien M. ;
Taubert, Dirk .
NATURE MEDICINE, 2011, 17 (01) :110-U287
[7]   No or only population-specific effect of PON1 on human longevity: A comprehensive meta-analysis [J].
Caliebe, Amke ;
Kleindorp, Rabea ;
Blanche, Helene ;
Christiansen, Lene ;
Puca, Annibale Alessandro ;
Rea, Irene Maeve ;
Slagboom, Eline ;
Flachsbart, Friederike ;
Christensen, Kaare ;
Rimbach, Gerald ;
Schreiber, Stefan ;
Nebel, Almut .
AGEING RESEARCH REVIEWS, 2010, 9 (03) :238-244
[8]   Paraoxonase and atherosclerosis-related cardiovascular diseases [J].
Chistiakov, Dimitry A. ;
Melnichenko, Alexandra A. ;
Orekhov, Alexander N. ;
Bobryshev, Yuri V. .
BIOCHIMIE, 2017, 132 :19-27
[9]   Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity [J].
Costa, LG ;
Cole, TB ;
Vitalone, A ;
Furlong, CE .
CLINICA CHIMICA ACTA, 2005, 352 (1-2) :37-47
[10]   A Genetic Biomarker of Oxidative Stress, the Paraoxonase-1 Q192R Gene Variant, Associates with Cardiomyopathy in CKD: A Longitudinal Study [J].
Dounousi, E. ;
Bouba, I. ;
Spoto, B. ;
Pappas, K. ;
Tripepi, G. ;
Georgiou, I. ;
Tselepis, A. ;
Elisaf, M. ;
Tsakiris, D. ;
Zoccali, C. ;
Siamopoulos, K. .
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2016, 2016